本文選題：硼替佐米 + 多發(fā)性骨髓瘤��； 參考：《腎臟病與透析腎移植雜志》2017年03期

【摘要】：正多發(fā)性骨髓瘤(MM)是來(lái)源于漿細(xì)胞克隆性增殖的血液系統(tǒng)惡性腫瘤。骨髓瘤細(xì)胞可分泌大量單克隆免疫球蛋白或其片段(M蛋白),臨床上常表現(xiàn)貧血、骨痛、溶骨性破壞、腎功能損害、反復(fù)感染等,目前仍無(wú)法治愈。初診的MM患者中,20%~28.2%存在腎功能損害(renal impairment,RI)[血清肌酐水平177μmol/L或2 mg/dl,或估算腎小球?yàn)V過(guò)率(eGFR)≤50
[Abstract]:Multiple myeloma (MMM) is a hematological malignant tumor derived from the clonal proliferation of plasma cells.Myeloma cells can secrete a large number of monoclonal immunoglobulin or its fragment of M protein, the clinical manifestations of anemia, bone pain, osteolytic destruction, renal function damage, repeated infection and so on, is still incurable.28. 2% of newly diagnosed MM patients have renal impairment renal impairmentRI [serum creatinine level 177 渭 mol/L or 2 mg / dl, or estimated glomerular filtration rate] 鈮，

本文編號(hào)：1770685